Hartaj Singh
Stock Analyst at Oppenheimer
(2.07)
# 2,805
Out of 4,712 analysts
104
Total ratings
39.36%
Success rate
-7.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $0.42 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $8.94 | +213.20% | 6 | Nov 14, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $95 → $105 | $92.37 | +13.67% | 13 | Nov 7, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,150 → $1,000 | $712.33 | +40.38% | 12 | Nov 6, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $352.84 | +70.05% | 7 | Oct 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $550 → $540 | $402.70 | +34.09% | 16 | Oct 30, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $41.58 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.80 | +455.56% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $3.88 | +1,446.39% | 5 | May 30, 2024 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $13 → $11 | $0.16 | +6,736.54% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 | $121.59 | +48.04% | 9 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $2.16 | +316.67% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.83 | +2,085.79% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $17.29 | +27.24% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.93 | +307.38% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.04 | +62,400.00% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $17.85 | +68.11% | 1 | Jan 26, 2018 |
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.42
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $8.94
Upside: +213.20%
Gilead Sciences
Nov 7, 2024
Maintains: Outperform
Price Target: $95 → $105
Current: $92.37
Upside: +13.67%
Regeneron Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $1,150 → $1,000
Current: $712.33
Upside: +40.38%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $352.84
Upside: +70.05%
Vertex Pharmaceuticals
Oct 30, 2024
Maintains: Outperform
Price Target: $550 → $540
Current: $402.70
Upside: +34.09%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $41.58
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.80
Upside: +455.56%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $3.88
Upside: +1,446.39%
Viracta Therapeutics
May 23, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.16
Upside: +6,736.54%
May 14, 2024
Upgrades: Outperform
Price Target: $180
Current: $121.59
Upside: +48.04%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $2.16
Upside: +316.67%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.83
Upside: +2,085.79%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $17.29
Upside: +27.24%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.93
Upside: +307.38%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.04
Upside: +62,400.00%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $17.85
Upside: +68.11%